Oakbrook Investments LLC decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 43.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,850 shares of the medical equipment provider’s stock after selling 9,950 shares during the quarter. Oakbrook Investments LLC’s holdings in Hologic were worth $471,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also modified their holdings of HOLX. Hall Laurie J Trustee boosted its position in Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after purchasing an additional 225 shares during the last quarter. Commonwealth Bank of Australia boosted its position in Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after purchasing an additional 600 shares during the last quarter. National Asset Management Inc. acquired a new stake in Hologic during the second quarter valued at $203,000. Beck Mack & Oliver LLC acquired a new stake in Hologic during the second quarter valued at $209,000. Finally, Notis McConarty Edward acquired a new stake in Hologic during the second quarter valued at $213,000. Institutional investors and hedge funds own 95.48% of the company’s stock.
Shares of Hologic, Inc. (NASDAQ HOLX) opened at 37.24 on Friday. The company has a market cap of $10.44 billion, a PE ratio of 13.87 and a beta of 0.91. The company has a 50 day moving average of $37.28 and a 200-day moving average of $41.49. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80.
Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. Hologic’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.51 earnings per share. Analysts forecast that Hologic, Inc. will post $2.01 EPS for the current fiscal year.
A number of research firms recently issued reports on HOLX. Bank of America Corporation reissued a “neutral” rating and set a $48.00 price objective (up previously from $44.00) on shares of Hologic in a research report on Friday, July 21st. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $51.00 price target on shares of Hologic in a research report on Friday, July 14th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Hologic in a research report on Friday, July 14th. BidaskClub cut Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, Barclays PLC reaffirmed an “overweight” rating and issued a $53.00 price target (up previously from $50.00) on shares of Hologic in a research report on Monday, July 17th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $47.77.
COPYRIGHT VIOLATION WARNING: This report was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.com-unik.info/2017/10/29/hologic-inc-holx-shares-sold-by-oakbrook-investments-llc.html.
In other news, Director Lawrence M. Levy sold 7,139 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $39.04, for a total transaction of $278,706.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Elaine Ullian sold 6,902 shares of the company’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total transaction of $276,908.24. Following the transaction, the director now owns 23,810 shares in the company, valued at approximately $955,257.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,775 shares of company stock worth $1,175,662. 0.79% of the stock is owned by company insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
What are top analysts saying about Hologic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic Inc. and related companies.